Display Settings:

Format

Send to:

Choose Destination
Health Aff (Millwood). 2011 Jan;30(1):84-90. doi: 10.1377/hlthaff.2009.1056.

The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial data.

Author information

  • 1Medicine and Public Policy, Leonard D Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, USAdana.goldman@usc.edu

Abstract

Pharmaceutical companies and generic drug manufacturers have long been at odds over "data exclusivity" regulations. These rules require a waiting period of at least five years before generic drug companies can access valuable clinical trial data necessary to bring less expensive forms of innovative drugs to market. Pharmaceutical companies want the data exclusivity period lengthened to protect their investment. Generic manufacturers want the period shortened so that they can bring less expensive versions of drugs to patients sooner. We examine the long-term effect of extending the data exclusivity period for conventional "small-molecule" drugs to twelve years--the same exclusivity period already extended to large-molecule biologic drugs under the Affordable Care Act. We conclude that Americans would benefit from a longer period of data exclusivity.

Comment in

PMID:
21209443
[PubMed - indexed for MEDLINE]
PMCID:
PMC3804334
Free PMC Article

Images from this publication.See all images (4)Free text

EXHIBIT 1
EXHIBIT 2
EXHIBIT 3
EXHIBIT 4
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk